	US 11,771,758 B2
	Compositions including SBI adjuvants and methods of use thereof
Kyle Backman, Arlington, MA (US); Nikhil Dhar, Boston, MA (US); Nikolai Eroshenko, Boston, MA (US); Taylor Gill, Cambridge, MA (US); Kemo Jammeh, Cambridge, MA (US); Marianna Keaveney, Walpole, MA (US); Justin Quinn, Malden, MA (US); Hannu Rajaniemi, Point Richmond, CA (US); and Everett Webster, North Andover, MA (US)
Assigned to Helix Nanotechnologies, Inc., Boston, MA (US)
Filed by Helix Nanotechnologies, Inc., Walnut, CA (US)
Filed on Mar. 3, 2022, as Appl. No. 17/685,717.
Claims priority of provisional application 63/156,860, filed on Mar. 4, 2021.
Prior Publication US 2022/0362373 A1, Nov. 17, 2022
Int. Cl. C07K 14/47 (2006.01); A61K 39/215 (2006.01); C07K 14/11 (2006.01); C07K 14/165 (2006.01); C07K 14/31 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [C07K 14/11 (2013.01); C07K 14/165 (2013.01); C07K 14/31 (2013.01); C07K 14/472 (2013.01); A61K 2039/575 (2013.01)]

27 Claims

1. A fusion polynucleotide comprising a nucleotide sequence encoding:

(i) a fragment antigen, an antigen variant, or a fragment antigen variant, that comprises an epitope of a target protein antigen, wherein the target protein antigen is or comprises:

(a) an infectious antigen chosen from a viral antigen or a fungal antigen or combinations thereof; or

(b) a cancer antigen; and

(ii) a complement C3d-binding polypeptide from an immunoglobulin-binding protein (Sbi) of Staphylococcus aureus,

wherein the fusion polynucleotide is RNA.